Shearman Mark S 4
4 · Editas Medicine, Inc. · Filed Dec 23, 2021
Insider Transaction Report
Form 4
Shearman Mark S
EVP, Chief Scientific Officer
Transactions
- Award
Common Stock
2021-12-22+9,084→ 41,785 total
Footnotes (1)
- [F1]Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 14, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 14, 2022, subject to continued service.